剖宫产术后静脉缩宫素预防产后出血的剂量方案:系统评价与荟萃分析
该系统评价与荟萃分析纳入35项研究(7333名妇女),比较剖宫产术后静脉缩宫素不同剂量方案预防产后出血的效果,发现证据有限且多数结果不确定;与单次推注联合输注相比,仅单次推注可能略增加平均失血量,初始推注剂量<5 IU可能减少恶心。
要点
- 与单次推注联合输注相比,仅单次推注可能略增加平均失血量(52 mL)。
- 推注联合输注方案中,初始推注剂量<5 IU可能减少恶心(RR 0.26)。
- 总剂量5-9 IU相比10-19 IU可能增加额外宫缩剂使用(RR 13.00)。
核心结论
- 比较剖宫产术后静脉缩宫素预防产后出血的方案证据有限,多数结果不确定。
- 推注联合输注方案可能小幅减少平均失血量,初始推注<5 IU可能减少恶心。
研究设计与样本
- 系统评价与荟萃分析,纳入35项研究(30项随机试验和5项非随机研究),共7333名妇女。
- 检索Ovid MEDLINE、Embase等数据库至2020年2月,两名作者独立筛选、提取数据并评估偏倚风险。
主要发现
- 与推注联合输注相比,仅单次推注可能略增加平均失血量(均差52 mL,95%CI 0.4-104 mL,中等确定性)。
- 推注联合输注方案中,初始推注剂量<5 IU相比5-9 IU可能减少恶心(RR 0.26,95%CI 0.11-0.63,低确定性)。
- 总剂量5-9 IU相比10-19 IU可能增加额外宫缩剂使用(RR 13.00,95%CI 1.75-96.37,低确定性)。
关键数值与推荐
- 主要结局为产后出血≥1000 mL的发生率。
- 其他结局包括额外宫缩剂使用、失血量和产妇不良事件。
- 采用GRADE评估证据确定性。
临床怎么用
- 剖宫产术后预防产后出血可考虑推注联合输注方案,初始推注剂量<5 IU可能减少恶心。
- 需权衡额外宫缩剂使用风险,总剂量选择应个体化。
局限性
- 大多数结局数据有限,结果多数不确定。
- 纳入研究包括非随机研究,部分结果基于低确定性证据。
- 对低血压等其他关键结局的影响尚需进一步比较试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the available evidence on intravenous oxytocin dosing regimens for the prevention of postpartum hemorrhage following cesarean delivery. DATA SOURCES: We searched Ovid MEDLINE, Embase, Global Index Medicus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Controlled Register of Trials, ClinicalTrials.gov, and the International Clinical Trials Registry Platform for eligible studies published until February 2020. STUDY ELIGIBILITY CRITERIA: We included any randomized or nonrandomized study published in peer-reviewed journals that compared at least 2 different dosing regimens of intravenous oxytocin for postpartum hemorrhage prevention in women undergoing cesarean delivery. METHODS: Two authors independently assessed the eligibility of studies, extracted the data, and assessed the risk of bias. The primary outcome was incidence of postpartum hemorrhage ≥1000 mL. Other review outcomes included use of additional uterotonics, blood loss, and adverse maternal events. Data were analyzed according to the type of intravenous administration (bolus only, infusion only, or bolus plus infusion) and total oxytocin dose. A meta-analysis was performed on randomized trials and the results were reported as risk ratios or mean differences with 95% confidence intervals. The Grading of Recommendations, Assessment, Development, and Evaluations scale was used to rate the certainty of evidence. Findings from dose-finding trials and nonrandomized studies were reported narratively. RESULTS: A total of 35 studies (7333 women) met our inclusion criteria and included 30 randomized trials and 5 nonrandomized studies. There were limited data available from the trials for most outcomes, and the results were not conclusive. Compared with bolus plus infusion regimens, bolus only regimens probably result in slightly higher mean blood loss (mean difference, 52 mL; 95% confidence interval, 0.4-104 mL; moderate certainty). Among the bolus plus infusion regimens, initial bolus doses <5 IU may reduce nausea (risk ratio, 0.26; 95% confidence interval, 0.11-0.63; low certainty) when compared with doses of 5-9 IU. Total oxytocin doses of 5-9 IU vs total doses of 10-19 IU may increase the use of additional uterotonics (risk ratio, 13.00; 95% confidence interval, 1.75-96.37; low certainty). Effects on other outcomes were generally inconclusive. CONCLUSION: There are limited data available for comparisons of IV oxytocin regimens for postpartum hemorrhage prevention following cesarean delivery. Bolus plus infusion regimens may lead to minor reductions in mean blood loss and initial bolus doses of <5 IU may minimize nausea. Bolus only regimens of 10 IU vs bolus only regimens of 5 IU may decrease the need for additional uterotonics, however, further comparative trials are required to understand the effects on other key outcomes, particularly hypotension.
引用
- Phung LC, Farrington EK, Connolly M, et al. Intravenous oxytocin dosing regimens for postpartum hemorrhage prevention following cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021. PMID: 33957113. doi:10.1016/j.ajog.2021.04.258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。